Pharmaceutical biotechnology companies focus on developing biologically-based medications and therapies. They bridge technology with biology to create drugs that harness the power of living cells. Companies in this sector often specialize in areas like cancer treatment, gene therapy, and rare disease vaccines. With rapid advancements in research methods and technologies, the industry is witnessing a surge in novel therapies entering the market, particularly those aimed at chronic diseases. As global demand for innovative treatments rises, investments are also increasing, fostering a vibrant environment for startups and established companies alike to thrive in this market.


The companies listed are a mix of private and corporate entities, primarily founded between the 1980s and 2010s. They vary in size from small firms with fewer than 100 employees to those with over 17,000, showcasing the broad spectrum of the industry. Most are headquartered in the USA or Europe, specializing in areas such as gene therapy, biosimilars, and advanced immunotherapies. Each company brings unique contributions to healthcare, underscoring their specialized crafting of innovative medical solutions.


Read on to learn more about the top pharmaceutical biotechnology companies.


Top 22 Pharmaceutical Biotechnology Companies


1. Seattle Genetics


Seattle Genetics, based in Bothell, Washington, is a biopharmaceutical company founded in 1998. The company focuses on developing and manufacturing innovative therapies, particularly in oncology. Seattle Genetics is known for its pioneering work in antibody-drug conjugates (ADCs), which combine targeted antibodies with potent cytotoxic drugs to treat various types of cancer. Their flagship product, Adcetris (brentuximab vedotin), has been approved for the treatment of certain lymphomas and has significantly impacted patient care. The company is dedicated to advancing cancer treatment through extensive research and development, aiming to bring new therapies to market that can improve patient outcomes. With a workforce of over 2,000 employees, Seattle Genetics continues to expand its product pipeline and explore new therapeutic areas, solidifying its position in the pharmaceutical biotechnology sector.


2. Octapharma

  • Website: octapharma.com
  • Ownership type: Private
  • Headquarters: Lachen, Schwyz, Switzerland
  • Employee distribution: Austria 24%, United States (USA) 23%, Sweden 15%, Other 38%
  • Founded year: 1983
  • Headcount: 10001+
  • LinkedIn: octapharma

Octapharma AG, founded in 1983 and headquartered in Lachen, Switzerland, is a prominent pharmaceutical company that specializes in the development and production of human proteins sourced from plasma and cell lines. The company operates as the largest privately owned and independent plasma fractionator globally, with a strong focus on therapeutic areas such as haematology, immunotherapy, and critical care. Octapharma's products are designed to treat rare diseases and coagulopathies, providing essential medicines to patients in 118 countries. The company maintains a robust network of plasma donation centers and manufacturing facilities, ensuring a steady supply of high-quality plasma for their therapies. Their commitment to safety and quality is reflected in their rigorous production processes, which include extensive testing and quality control measures. Octapharma is also engaged in ongoing research and development to innovate and expand their product offerings, demonstrating their dedication to advancing healthcare solutions.


3. FUJIFILM Diosynth Biotechnologies

  • Website: fujifilmdiosynth.com
  • Ownership type: Corporate
  • Headquarters: Morrisville, North Carolina, United States (USA)
  • Employee distribution: Denmark 43%, United States (USA) 40%, United Kingdom (UK) 17%
  • Latest funding: $890.0M, August 2019
  • Founded year: 2011
  • Headcount: 1001-5000
  • LinkedIn: fujifilm-diosynth-biotechnologies

FUJIFILM Diosynth Biotechnologies, founded in 2011, operates out of Morrisville, North Carolina, and has established itself as a prominent player in the biotechnology sector. The company specializes in contract development and manufacturing services, focusing on biologics, vaccines, and advanced therapies. They partner with pharmaceutical and biotechnology firms, providing expertise in cGMP processes to ensure the safe and effective delivery of products. With a workforce of over 5,000 employees distributed across the United States, Denmark, and the United Kingdom, FUJIFILM Diosynth Biotechnologies supports clients through all phases of drug development. Their capabilities include mammalian cell culture, microbial fermentation, and advanced therapies such as gene and cell therapy. The company has made substantial investments in expanding its facilities and capabilities, reflecting its commitment to meeting the evolving needs of the pharmaceutical industry.


4. Eisai Co., Ltd.


Eisai Co., Ltd., founded in 1941 and based in Bunkyo City, Tokyo, Japan, is a pharmaceutical company dedicated to drug discovery and development. The company specializes in creating innovative treatments for various health conditions, with a strong focus on oncology and neurology. Eisai aims to enhance patient outcomes and improve access to medicines through its extensive research and development efforts. The company operates globally, with a significant presence in Japan, Vietnam, the United States, and other countries. Eisai is also involved in various initiatives aimed at improving access to medicines, particularly in developing regions, and has a robust pipeline of clinical trials that reflect its commitment to advancing healthcare solutions.


5. Bharat Biotech

  • Website: bharatbiotech.com
  • Ownership type: Venture Capital
  • Headquarters: Hyderabad, Telangana, India
  • Employee distribution: India 99%
  • Latest funding: Other (Grant), $14.1M, June 2020
  • Founded year: 1996
  • Headcount: 1001-5000
  • LinkedIn: bharat-biotechil

Bharat Biotech International Limited, founded in 1996 and based in Hyderabad, India, specializes in the development and manufacturing of vaccines and biotherapeutics. The company has a strong emphasis on research and development, with over 220 patents to its name. Bharat Biotech has made significant contributions to public health, particularly in developing countries, by providing innovative solutions to combat infectious diseases. Their product lineup includes a range of vaccines, such as Biohib, Biopolio, and the notable COVAXIN, which was one of the first COVID-19 vaccines approved for emergency use in India. The company has delivered over 9 billion vaccine doses globally, showcasing its extensive reach and impact. Bharat Biotech's manufacturing facilities are compliant with international standards, having received approvals from the USFDA, KFDA, and WHO. Their recent funding of $14.1 million in 2020 further supports their ongoing research initiatives and product development efforts.


6. Spark Therapeutics, Inc.

  • Website: sparktx.com
  • Ownership type: Corporate
  • Headquarters: Philadelphia, Pennsylvania, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: $4.3B, February 2019
  • Founded year: 2013
  • Headcount: 501-1000
  • LinkedIn: spark-therapeutics-inc

Spark Therapeutics, Inc., founded in 2013 and based in Philadelphia, Pennsylvania, is a biotechnology firm dedicated to developing gene therapy treatments for genetic disorders. The company emerged from two decades of research at the Children's Hospital of Philadelphia, leveraging extensive expertise in gene therapy. Spark Therapeutics aims to create innovative, one-time therapies that can significantly improve the lives of patients suffering from conditions that currently have limited treatment options. Their focus areas include inherited retinal diseases and hemophilia, where they are actively conducting research and clinical trials. Spark's proprietary adeno-associated viral (AAV) gene therapy platform is central to their operations, allowing them to design targeted therapies for specific genetic conditions. The company is also expanding its capabilities with the construction of a new Gene Therapy Innovation Center, which will enhance their manufacturing and research efforts. Spark Therapeutics is a member of the Roche Group, further solidifying its position in the biotechnology industry.


7. Adimab

  • Website: adimab.com
  • Ownership type: Venture Capital
  • Headquarters: Lebanon, New Hampshire, United States (USA)
  • Employee distribution: United States (USA) 96%, Lebanon 4%
  • Latest funding: January 2020
  • Founded year: 2007
  • Headcount: 51-200
  • LinkedIn: adimab-llc

Adimab, founded in 2007 and based in Lebanon, New Hampshire, is a biotechnology company that focuses on biologics discovery and engineering. The company specializes in developing therapeutic antibodies and multispecifics, collaborating with a range of pharmaceutical and biotech partners. Over its 15 years of operation, Adimab has successfully generated more than 500 therapeutic programs, showcasing its robust capabilities in antibody discovery. The company utilizes a proprietary yeast-based platform that leverages both synthetic and immunized diversity to produce fully human IgGs, single domain antibodies, and multispecific leads. This technology is designed to address the complexities of drug development, making Adimab a valuable partner in the pharmaceutical biotechnology sector.


8. Samsung Bioepis

  • Website: samsungbioepis.com
  • Ownership type: Corporate
  • Headquarters: Yeonsu-Gu, Incheon, South Korea
  • Employee distribution: South Korea 91%, Netherlands 3%, Other 6%
  • Latest funding: January 2022
  • Founded year: 2012
  • Headcount: 501-1000
  • LinkedIn: samsungbioepis

Samsung Bioepis is a biopharmaceutical company based in Yeonsu-Gu, Incheon, South Korea, founded in 2012. The company focuses on the development and commercialization of biosimilar medicines, aiming to improve patient access to high-quality biologic therapies. Their product portfolio includes biosimilars for key therapeutic areas such as immunology and oncology, with recent expansions into ophthalmology, gastroenterology, and hematology. Samsung Bioepis has achieved significant milestones, including the first European approvals for several biosimilars targeting autoimmune conditions. The company collaborates with partners like Biogen, Organon, and Sandoz to ensure the global availability of its products. With a workforce of around 1,584 employees, Samsung Bioepis is committed to innovation and quality in the biopharmaceutical sector.


9. PROBIOMED S.A. de C.V.

  • Website: probiomed.com.mx
  • Ownership type: Corporate
  • Headquarters: Mexico
  • Employee distribution: Mexico 99%
  • Latest funding: May 2022
  • Founded year: 1970
  • Headcount: 501-1000
  • LinkedIn: probiomedmx

PROBIOMED S.A. de C.V. is a Mexican biopharmaceutical company established in 1970. The company specializes in the research, development, manufacturing, and commercialization of pharmaceutical products designed to enhance human health. With a workforce of approximately 657 employees, PROBIOMED is dedicated to providing high-tech biopharmaceutical solutions that improve the quality of life for patients. Their product portfolio includes a wide array of therapies targeting serious diseases, including cancer, chronic kidney disease, rheumatoid arthritis, multiple sclerosis, and diabetes. The company emphasizes the importance of accessibility to effective treatments, aiming to reach patients not only in Mexico but also around the world. PROBIOMED's offerings include chemical synthesis generics and biocomparables, such as cytokines, monoclonal antibodies, fusion proteins, and recombinant vaccines, which are crucial for treating autoimmune diseases, chronic degenerative disorders, hematological and metabolic disorders, as well as malignant neoplasms.


10. Intas Pharmaceuticals

  • Website: intaspharma.com
  • Ownership type: Private Equity
  • Headquarters: Ahmedabad, Gujarat, India
  • Employee distribution: India 99%, Other 1%
  • Latest funding: October 2022
  • Founded year: 2000
  • Headcount: 10001+
  • LinkedIn: intas-biopharmaceuticals

Intas Pharmaceuticals Limited, founded in 2000 and based in Ahmedabad, Gujarat, India, is a pharmaceutical company that focuses on the development, manufacturing, and marketing of generic therapeutic drugs. With a workforce exceeding 17,000 employees, Intas operates primarily in India, but its reach extends to over 85 countries worldwide. The company is dedicated to addressing unmet medical needs through innovative products and a strong commitment to quality. Intas invests approximately 6-7% of its turnover into research and development, employing over 550 scientists and researchers across 17 advanced facilities. Their product portfolio includes a range of formulations, from tablets to injectables, and they have made significant strides in areas such as biosimilars and cell and gene therapy. Intas is recognized for its high-quality standards, with manufacturing facilities accredited by major global regulatory agencies, including the USFDA and EMA. This commitment to quality and innovation positions Intas as a notable player in the pharmaceutical biotechnology sector.


11. Dendreon

  • Website: dendreon.com
  • Ownership type: Corporate
  • Headquarters: Seal Beach, California, United States (USA)
  • Employee distribution: United States (USA) 97%, Other 3%
  • Latest funding: $819.9M, June 2017
  • Founded year: 1992
  • Headcount: 501-1000
  • LinkedIn: dendreon

Dendreon Pharmaceuticals LLC, based in Seal Beach, California, is a biotechnology firm that focuses on immunotherapy for cancer treatment. Founded in 1992, the company is known for its flagship product, Provenge (sipuleucel-T), which is the first FDA-approved immunotherapy that utilizes a patient's own immune cells to treat advanced prostate cancer. Since its approval in 2010, Provenge has been administered to nearly 40,000 men, demonstrating its impact on patient outcomes. In addition to its therapeutic offerings, Dendreon provides cellular therapy manufacturing services, supporting the development of innovative cancer therapies. The company is committed to improving patient lives through advanced medical solutions and continues to invest in research and clinical trials to explore the potential of its therapies further.


12. Kedrion Biopharma

  • Website: kedrion.com
  • Ownership type: Private Equity
  • Headquarters: Fort Lee, New Jersey, United States (USA)
  • Employee distribution: Italy 49%, United States (USA) 27%, United Kingdom (UK) 14%, Other 11%
  • Latest funding: September 2022
  • Founded year: 2001
  • Headcount: 1001-5000
  • LinkedIn: kedrion-biopharma

Kedrion Biopharma is a biopharmaceutical company based in Fort Lee, New Jersey, established in 2001. The company specializes in the collection and fractionation of blood plasma to produce and distribute therapies aimed at treating rare and debilitating diseases. Their product portfolio includes treatments for conditions such as coagulation disorders and immunodeficiencies. Kedrion operates globally, with production facilities in multiple countries and a network of plasma collection centers in the United States and the Czech Republic. The company has expanded its capabilities through strategic acquisitions, including the purchase of Bio Products Laboratory in 2022, enhancing its position in the market for plasma-derived medicines. Kedrion is dedicated to maintaining high industry standards and ensuring the safety and efficacy of its products, which are distributed in over 100 countries worldwide.


13. Pooyesh Darou Biopharmaceutical Co.


Pooyesh Darou Biopharmaceutical Co., based in Tehran, Iran, was founded in 1997 and has since become a prominent biotechnology company in the region. Specializing in the production of recombinant biopharmaceuticals, the company manufactures therapeutic proteins aimed at addressing various medical needs. Pooyesh Darou operates under strict quality control measures and adheres to international standards, ensuring that their products are safe and effective. They have developed a range of recombinant proteins, including Granulocyte Colony Stimulating Factor and Erythropoietin, and maintain a significant market share in Iran's biopharmaceutical sector. The company has also established partnerships with academic and research institutions to enhance their research and development capabilities, further solidifying their position in the industry.


14. Amgen Deutschland

  • Website: amgen.de
  • Ownership type: Private
  • Headquarters: Munich, Bavaria, Germany
  • Employee distribution: Germany 97%, Jordan 3%
  • Founded year: 1989
  • Headcount: 501-1000
  • LinkedIn: amgengermany

Amgen Deutschland, based in Munich, Bavaria, is a biotechnology company that has been operational since 1989. The company focuses on developing innovative therapies for serious diseases, with a strong emphasis on oncology and chronic inflammatory conditions. Amgen Deutschland offers a range of biopharmaceutical products and biosimilars, aiming to enhance patient outcomes through advanced medical solutions. The company is deeply committed to research and development, striving to understand biological mechanisms of diseases and improve treatment options. They also engage with healthcare providers and patients, ensuring that their therapies meet the needs of those they serve. Additionally, Amgen Deutschland participates in various educational programs, such as the Amgen Scholars Europe Program, to foster interest in biotechnology among students and young researchers.


15. Nimbus Therapeutics

  • Website: nimbustx.com
  • Ownership type: Venture Capital
  • Headquarters: Boston, Massachusetts, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: $210.0M, September 2023
  • Founded year: 2009
  • Headcount: 51-200
  • LinkedIn: nimbus-therapeutics

Nimbus Therapeutics, founded in 2009 and based in Boston, Massachusetts, is a biotechnology firm dedicated to the discovery and development of small molecule therapeutics. The company specializes in tackling complex diseases, particularly in the fields of immunology, oncology, and metabolism. By utilizing advanced drug discovery techniques, Nimbus aims to create innovative treatment solutions that can significantly impact patient care. Their approach involves a collaborative structure-based drug discovery engine, which leverages high-resolution protein structural data to identify and drug targets that are often overlooked by other companies. With a recent funding round of $210 million in September 2023, Nimbus Therapeutics continues to attract attention and resources, underscoring its active role in the pharmaceutical biotechnology sector.


16. Aimmune Therapeutics

  • Website: aimmune.com
  • Ownership type: Corporate
  • Headquarters: Brisbane, California, United States (USA)
  • Employee distribution: United States (USA) 81%, United Kingdom (UK) 10%, Switzerland 5%, Other 4%
  • Latest funding: $2.6B, August 2020
  • Founded year: 2011
  • Headcount: 501-1000
  • LinkedIn: aimmune-therapeutics

Aimmune Therapeutics, based in Brisbane, California, is a biopharmaceutical company founded in 2011. The company is dedicated to developing innovative therapies aimed at treating food allergies and related gastrointestinal and metabolic diseases. Aimmune's mission is to transform the lives of patients and their families by providing effective, science-driven treatments that help manage these conditions. They actively collaborate with other biotechnology firms to enhance their research and development efforts. Aimmune has garnered significant financial support, with a reported funding amount of $2.6 billion as of August 2020, reflecting strong investor interest in their specialized focus on food allergies. This funding enables them to advance their pipeline of therapies and contribute to the healthcare sector's understanding and management of food-related health issues.


17. PlantForm Corporation

  • Website: plantformcorp.com
  • Ownership type: Venture Capital
  • Headquarters: Toronto, Ontario, Canada
  • Employee distribution: Canada 91%, Brazil 9%
  • Latest funding: Other (Grant), $25,000, February 2018
  • Founded year: 2008
  • Headcount: 11-50
  • LinkedIn: plantform-corporation

PlantForm Corporation, based in Toronto, Ontario, is a biopharmaceutical company established in 2008. The company specializes in the rapid development and production of specialty antibody and protein drugs through its proprietary _vivo_ XPRESS® technology platform. This plant-based system allows for efficient and cost-effective production of biologic drugs, catering to pharmaceutical companies and research institutions. PlantForm's product pipeline includes biosimilars for well-known drugs such as pembrolizumab (Keytruda®) and ranibizumab (Lucentis®), as well as innovative medical countermeasures for biological threats. The company has received funding, including a grant of $25,000 in 2018, which supports its ongoing research and development efforts. With a focus on addressing critical health challenges, PlantForm is positioned as a significant player in the pharmaceutical biotechnology industry.


18. Calico Life Sciences

  • Website: calicolabs.com
  • Ownership type: Venture Capital
  • Headquarters: South San Francisco, California, United States (USA)
  • Employee distribution: United States (USA) 99%, Other 1%
  • Latest funding: Seed, January 2021
  • Founded year: 2013
  • Headcount: 201-500
  • LinkedIn: calico-life-sciences-llc

Calico Life Sciences LLC, founded in 2013 and based in South San Francisco, California, is a biotechnology company dedicated to research and development in the field of aging and age-related diseases. The company aims to harness advanced technologies to deepen the understanding of aging biology and to create innovative therapies that can improve healthspan. With a workforce of approximately 384 employees, Calico operates primarily in the United States and collaborates with various academic and biopharmaceutical partners to advance its research initiatives. Their clinical trials focus on conditions such as Vanishing White Matter Disease and Amyotrophic Lateral Sclerosis, showcasing their commitment to translating research into potential treatments. Calico's mission is ambitious, seeking to tackle one of the most complex biological challenges—aging—through a combination of cutting-edge science and collaborative partnerships.


19. NPS Pharma

  • Website: shire.com
  • Ownership type: Corporate
  • Headquarters: Bedminster, New Jersey, United States (USA)
  • Employee distribution: United States (USA) 51%, Algeria 12%, Ireland 12%, Other 25%
  • Latest funding: $86.4B, April 2018
  • Founded year: 1986
  • Headcount: 201-500
  • LinkedIn: nps-pharmaceuticals

NPS Pharma, a subsidiary of Takeda Pharmaceutical Company Limited, is based in Bedminster, New Jersey. Founded in 1986, the company specializes in the research, development, manufacturing, and marketing of innovative medicines. NPS Pharma is particularly focused on therapeutic areas such as gastrointestinal diseases, rare diseases, oncology, and vaccines. The company aims to transform the lives of patients by providing treatments for conditions that often lack effective solutions. With a workforce of approximately 148 employees, NPS Pharma is committed to advancing medical science and improving patient outcomes globally. The company has received significant funding, amounting to over $86 billion, which underscores its potential for growth and innovation in the pharmaceutical biotechnology sector.


20. Sanyou Biopharmaceuticals Co., Ltd.

  • Website: sanyoubio.com
  • Ownership type: Private Equity
  • Headquarters: Cambridge, Massachusetts, United States (USA)
  • Latest funding: Series B, August 2022
  • Founded year: 2015
  • Headcount: 201-500
  • LinkedIn: sanyou-biopharmaceuticals-co-ltd

Sanyou Biopharmaceuticals Co., Ltd., founded in 2015 and based in Cambridge, Massachusetts, is a private equity-backed biopharmaceutical company. The firm specializes in the research and development of innovative biological drugs, providing a range of services that include integrated R&D platforms, antibody development, and protein production. Their clientele primarily consists of pharmaceutical companies and research institutions that seek advanced solutions for drug development. Sanyou operates on a global scale, with multiple locations in the United States and China, reflecting their commitment to serving a broad market. The company has not reported any recent funding, indicating a stable operational status since its last funding round in August 2022.


21. Sanofi Belgium

  • Website: sanofi.be
  • Ownership type: Private
  • Headquarters: Machelen, Flanders, Belgium
  • Employee distribution: Belgium 99%
  • Founded year: 2004
  • Headcount: 501-1000
  • LinkedIn: sanofi-belgium

Sanofi Belgium, established in 2004 and located in Machelen, Flanders, is a private pharmaceutical company that specializes in the research, development, and production of innovative medicines and therapies. With a workforce of approximately 1,600 employees across four sites in Belgium, Sanofi Belgium covers the entire pharmaceutical value chain. This includes conducting clinical studies, producing biological medicines, and managing the registration, commercialization, and distribution of these products. Their Geel facility is particularly noteworthy, as it focuses on producing therapeutic proteins through cell culture, contributing to the global network of Sanofi's biopharmaceutical production. The company is also engaged in developing advanced therapeutic technologies, such as NANOBODY®, a unique type of therapeutic protein. Sanofi Belgium's commitment to improving health outcomes for chronic and rare diseases is evident in their ongoing investments and initiatives aimed at enhancing their production capabilities and expanding their research efforts.


22. Alzheon, Inc. | Preserving Future Memories

  • Website: alzheon.com
  • Ownership type: Venture Capital
  • Headquarters: Framingham, Massachusetts, United States (USA)
  • Employee distribution: United States (USA) 93%, Czech Republic 7%
  • Latest funding: Series E-K, $100.0M, June 2024
  • Founded year: 2013
  • Headcount: 11-50
  • LinkedIn: alzheon

Alzheon, Inc. is a biotechnology firm based in Framingham, Massachusetts, founded in 2013. The company is dedicated to developing innovative treatments for Alzheimer's disease, a condition that affects millions worldwide. Their flagship product, valiltramiprosate (ALZ-801), is currently undergoing Phase 3 clinical trials, specifically targeting patients with the APOE4/4 genotype. This focus reflects a precision medicine approach, aiming to address the needs of a high-risk patient population. Alzheon has engaged in extensive research and development, supported by significant funding, including a recent $100 million investment. The company has also received grants from the National Institute on Aging, further validating its research efforts. Alzheon is committed to addressing the unmet medical needs in Alzheimer's care, with the potential to introduce the first oral treatment that could slow or halt disease progression.



Pharmaceutical Biotechnology Insights: Key Companies


CompanyHeadquarterSizeFoundedOwnership
Seattle GeneticsBothell, Washington, United States (USA)1001-50001998Private
OctapharmaLachen, Schwyz, Switzerland10001+1983Private
FUJIFILM Diosynth BiotechnologiesMorrisville, North Carolina, United States (USA)1001-50002011Corporate
Eisai Co., Ltd.Bunkyo City, Tokyo, Japan1001-50001941Private
Bharat BiotechHyderabad, Telangana, India1001-50001996Venture Capital
Spark Therapeutics, Inc.Philadelphia, Pennsylvania, United States (USA)501-10002013Corporate
AdimabLebanon, New Hampshire, United States (USA)51-2002007Venture Capital
Samsung BioepisYeonsu-Gu, Incheon, South Korea501-10002012Corporate
PROBIOMED S.A. de C.V.Mexico501-10001970Corporate
Intas PharmaceuticalsAhmedabad, Gujarat, India10001+2000Private Equity
DendreonSeal Beach, California, United States (USA)501-10001992Corporate
Kedrion BiopharmaFort Lee, New Jersey, United States (USA)1001-50002001Private Equity
Pooyesh Darou Biopharmaceutical Co.Tehran, Tehran, Iran201-5001997Private
Amgen DeutschlandMunich, Bavaria, Germany501-10001989Private
Nimbus TherapeuticsBoston, Massachusetts, United States (USA)51-2002009Venture Capital
Aimmune TherapeuticsBrisbane, California, United States (USA)501-10002011Corporate
PlantForm CorporationToronto, Ontario, Canada11-502008Venture Capital
Calico Life SciencesSouth San Francisco, California, United States (USA)201-5002013Venture Capital
NPS PharmaBedminster, New Jersey, United States (USA)201-5001986Corporate
Sanyou Biopharmaceuticals Co., Ltd.Cambridge, Massachusetts, United States (USA)201-5002015Private Equity
Sanofi BelgiumMachelen, Flanders, Belgium501-10002004Private
Alzheon, Inc. | Preserving Future MemoriesFramingham, Massachusetts, United States (USA)11-502013Venture Capital


Want to Find More Pharmaceutical Biotechnology Companies?

If you want to find more companies that offer innovative therapies and biopharmaceutical solutions to patients you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

  • Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
  • Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
  • Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!